DDR2 and breast cancer: In addition, Liu inhibited the progression of estrogen receptor-positive breast cancer by constructing MiR-4458-loaded gelatin nanospheres targeting COL11A1 to block the DDR2/SRC signaling pathway (Liu et al., 2022).